Hypothermia in patients with cardiac arrest prior to ECMO-VA: Insight from the HYPO-ECMO trial
Primary result · Primary outcome, MH vs normothermia, CA subgroupResult — go to the resultRD −13.3 % CI −16.3 to −0.3%Authors' conclusion
This post hoc analysis suggests that MH shows potential for reducing mortality and composite endpoints in patients with cardiac arrest and refractory CS treated with VA-ECMO without an increased risk of severe bleeding or infection.
Study context
- Population
- Intubated patients receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock for <6 h, 20 French centres, 2016–2019completed trial
- Participants
- 334 patients
- Comparison
- Moderate hypothermia vs normothermia in patients with cardiac arrest (CA) before VA-ECMO
- CAn = 159
- Primary endpoint
- Treatment effect of MH in the CA subgroup
Methodological detailspost hoc, non-predefined, subgroup analysis, multicentre
- Post hoc
- Non-predefined
- Subgroup analysis
- Multicentre
Primary result
Primary outcome, MH vs normothermia, CA subgroup
RD
−13.3 %
CI −16.3 to −0.3%
P = 0.031
MH vs Normothermia
RD −13.3 % (CI −16.3 to −0.3%); P = 0.031
As reported in the abstract
- Moderate hypothermia (MH) associated with significant reduction in secondary outcomes in CA group only
- P < 0.025 for all
Secondary outcomes
| Outcome | CA | no-CA | Estimate | P value | |
|---|---|---|---|---|---|
| Mortality, CA vs no-CA · 30 and 180 days30 days | adjusted RD 8.1 % (CI −0.8 to 17.1%) | P = 0.074 | |||
| 30-day mortality | 50.9% | 42.3% | |||
| 180-day mortality | 59.1% | 51.4% | |||
| Mortality, CA vs no-CA · 30 and 180 days180 days | RD 7.0 % (CI −3.0 to 16.9%) | P = 0.17 | |||
| −1001020Difference, % (linear scale) |
Original publication
Hypothermia in patients with cardiac arrest prior to ECMO-VA: Insight from the HYPO-ECMO trial. Resuscitation. Published 17 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →